Boehringer Ingelheim inks another deal on liver disease

8 November 2017

German family-owned pharma major Boehringer Ingelheim is stepping up its game in liver disease through the second liver disease/RNA partnership within a week.

Boehringer Ingelheim and UK-based MiNA Therapeutics, part of the Japanese Sosei Group (TYO Mothers: 4565) and a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as non-alcoholic steatohepatitis (NASH), based on MiNA’s small activating RNA (saRNA) therapeutics platform.

Earlier this month, Boehringer Ingelheim signed an agreement with Dicerna Pharmaceuticals (Nasdaq: DRNA), a US developer of investigational RNA interference (RNAi) therapeutics, to discover and develop novel GalXC RNAi therapeutics for the treatment of chronic liver diseases, worth a potential $200 million to Dicerna.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK